Recently Featured

An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?

May 6, 2026
A new artificial intelligence tool is poised to revolutionize drug research and development by acting as a virtual team of highly skilled researchers. This innovation, described as a “data center full of genius Ph.D. students in their pocket,” enables pharmaceutical companies to harness vast amounts of data more efficiently than traditional methods allow. The implications…

MSD-backed Ray locks in $125m to back eye drug pipeline

May 6, 2026
Ray Therapeutics has successfully secured $125 million in a Series B funding round, backed by MSD and Novo Holdings, to advance its innovative gene therapy pipeline aimed at vision restoration. This significant investment underscores the growing interest and potential in gene therapies for ocular diseases, a sector that has seen limited advancements in recent years.…

AbbVie to establish NC production base with $1.4B investment, creating 730-plus jobs

May 6, 2026
AbbVie has announced a significant $1.4 billion investment to establish a new manufacturing facility in North Carolina, which is expected to create over 730 jobs in the region. This move underscores the company’s commitment to expanding its production capabilities in response to increasing global demand for biopharmaceuticals. The decision to invest in North Carolina aligns…

Amneal Seizes ‘Golden Era’ for Biosimilars with $1.1B Kashiv Buyout

May 5, 2026
Amneal Pharmaceuticals has announced its strategic acquisition of Kashiv BioSciences for $1.1 billion, marking a significant move in the evolving biosimilars market. This acquisition comes at a time when the biosimilars sector is gaining unprecedented momentum, driven by increasing demand for cost-effective alternatives to biologic therapies. Chirag Patel, co-CEO of Amneal, highlighted this period as…

Ongoing Cases